Article Text

Download PDFPDF

Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo
  1. B Vander Cruyssen,
  2. F De Keyser,
  3. E Kruithof,
  4. H Mielants,
  5. F Van den Bosch
  1. Department of Rheumatology, Ghent University Hospital, Gent, Belgium
  1. Correspondence to:
    B Vander Cruyssen
    Department of Rheumatology, Ghent University Hospital, B-9000 Gent, Belgium; bert.vandercruyssen{at}

Statistics from

Psoriatic arthritis (PsA) shares features with the spondyloarthropathy (SpA) concept and with rheumatoid arthritis. Treatment of PsA should target the skin, the SpA-like features and the rheumatoid arthritis-like features of the disease. Effects of treatment can be measured by one index covering different axes at once or by evaluating each axis separately.1 In this analysis, we evaluated different composite indices that have been validated in rheumatoid arthritis and compared them with the Psoriatic Arthritis Response Criteria (PsARC).2

The study population consisted of 18 patients with PsA, previously enrolled in a randomised monocentre double-blind placebo-controlled study evaluating effect of infliximab in patients with SpA,3 of whom nine received placebo. Patients were evaluated at baseline and at weeks 1, 2, 6, 8 and 12, which included the evaluation of the single components included in the PsARC, the Disease Activity Score using 28 joint counts (DAS28)4 and the DAS response ( A modified American College of Rheumatology (mACR) response was calculated by using the Bath Ankylosing Spondylitis Functional Index or the Dougados Functional Index instead of the Health Assessment Questionnaire.4–6

Although only 18 patients were included in our study, this was enough to assess the values of the different outcome measures in patients with PsA, as reflected by the considerable differences between groups after treatment. The results of the mACR response were identical whether the Bath Ankylosing Spondylitis Functional Index or the Dougados Functional Index was used. PsARC, mACR20 and DAS28 responses were similarly effective in distinguishing between the two treatment groups (table 1). The mACR and the DAS28 responses can be used as a dichotomous (response yes or no) variable, and also as ordinal variables (0/20/50/70 response for the mACR response and no/moderate/good response for the DAS28). The evaluation of such ordinal categories by a special measure of association (such as the ordinal γ statistic7) adds statistical power (table 1).

Table 1

 Baseline characteristics of patients’ and comparison of the different outcome measures evaluating the effects of treatment

DAS28 as a continuous variable can be evaluated by measuring changes over time or by comparing the remaining disease activity at week 12 between the two treatment arms (table 1). The effect size8 and standardised response mean9 of DAS28 were 1.9 and 1.7, respectively in the infliximab treated group; similar results were observed in patients with PsA and in those with rheumatoid arthritis (personal observations). Profiles over time can be evaluated by comparing areas under the curve (table 1) or by linear mixed-models analysis. Mixed-models analysis can correct for small differences in baseline conditions between groups.8 We therefore fitted a general linear mixed model with DAS28 as the outcome variable resulting in a significant effect of the treatment over time, reflected by a significant treatment effect at week 2 (mean = −1.15 v baseline; p = 0.016), week 6 (mean = −2.12 v baseline; p<0.001) and week 12 (mean = −2.39 v baseline; p<0.001), resulting in a highly significant global treatment effect (Fisher’s exact test p<0.001).

DAS28 and other variables, such as tender or swollen joint counts, can be used as continuous outcome measures, evaluated at different time points. However, as shown in fig 1, DAS28 can distinguish more efficiently between the two treatment groups than among each of its four components alone (less overlap of error bars) or the 66/68 joint counts. This also suggests that the reduction in the number of evaluable joints by the use of a 28-joint count does not affect the efficacy of the DAS28.

Figure 1

 Plots of the Disease Activity Score for the 28-joint count (DAS28) score and different single measures. (A) Evolution of the DAS28 over time. (B–E) Evolution of the components of the DAS28 over time. (F,G) Evolution of 66 and 68 swollen and tender joint counts over time. There is more overlap of the error bars of the individual components and the 66 and 68 swollen joint counts than the DAS28. ESR, erythrocyte sedimentation rate at first hour; ln, natural logarithm; sqrt, squared root. Error bars show mean (2 SE).

In conclusion, we evaluated different outcome measures and statistical methods related rheumatoid arthritis to measure effects of treatment in patients with PsA. We showed that the different response scores are equally efficient. Also, the DAS28, as a measure of absolute disease activity, can be used as a powerful tool to evaluate effects of treatment in patients with PsA.


BVC was supported by a concerted action grant GOA 2001/12051501 from Ghent University, Belgium. This study was supported by a grant from Centocor and Schering Plough. We thank Mrs Ilse Ghyselinck for her assistance with the data collection.


View Abstract


  • Competing interests: None declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.